Diabetic macular edema(DME)is one of the common eye complications in diabetic patients, and is also the main cause of visual impairment in diabetic patients. Vascular endothelial growth factor(VEGF)is currently an important target for DME therapy, the latest DME guidelines point out that anti-VEGF can be used as a first-line treatment for all types of DME. Anti-VEGF and glucocorticoid are widely used medications in DME treatment at present. Besides, numbers of new therapies which include anti-VEGF DARPin(designed ankyrin repeat proteins, DARPins), vascular adhesion protein, integrin antagonists and others, are in development. This article reviews the medication and emerging treatment of diabetic macular edema.